<DOC>
	<DOCNO>NCT00943943</DOCNO>
	<brief_summary>The goal clinical research study learn tolerable dose Nexavarâ ( sorafenib ) give combination Mobozilâ ( plerixafor ) Neupogenâ ( filgrastim ) patient AML . The safety combination also study . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Granulocyte-colony Stimulating Factor ( G-CSF ) Plerixafor Plus Sorafenib Acute Myelogenous Leukemia ( AML ) With FLT3 Mutations</brief_title>
	<detailed_description>The Study Drugs : Sorafenib type drug call multikinase inhibitor . It design interfere part cancer cell involve send chemical message help cell divide grow , may block formation tumor cause cell death . Filgrastim promote growth white blood cell , help fight infection . Plerixafor design help move stem cell bone marrow blood . Study Drug Dose Level : If participant find eligible take part study , assign dose level schedule sorafenib base join study . Up 5 dose level schedule test . Three ( 3 ) participant enrol dose level Phase I study . The first group participant receive dose level `` 0 '' sorafenib . If unacceptable side effect see , dose low level `` 0 '' try . If side effect see , next group 3 participant place high dose level , call Level `` 1 . '' Each new group either receive high low dose sorafenib take less often group , base whether intolerable side effect see . This continue best tolerable dose schedule sorafenib find . Once best tolerable dose and/or schedule find , last 10 participant enrol take sorafenib dose schedule . This last group 10 consider early Phase II part study . Each group receive dose level schedule filgrastim plerixafor . Study Drug Administration : Participant receive filgrastim plerixafor injection needle skin Day 1 ( day study start ) every day total 7 dos . The injection give morning . After day one , injection may do participant 's home . Participant 's study doctor meet one-on-one discuss drug give . On Day 1 , participant begin take dose sorafenib mouth every day , day , twice day , depend join study . - If participant take sorafenib every day , Cycle 1 start take 12 hour filgrastim plerixafor injection ( next morning ) . - If participant take sorafenib every day , take time every morning . The first time participant take sorafenib Cycle 1 12 hour first filgrastim plerixafor injection . - If participant take sorafenib twice day , Cycle 1 start take 12 hour filgrastim plerixafor injection every 12 hour . Participant take sorafenib without food , least 1 hour 2 hour eat . If participant miss dose , take double dose next time make miss dose . These 28 day one `` study cycle '' . Participant allow take hydroxyurea treatment control high white blood cell count . Study Drug Diary : Participant give study drug diary expect fill whenever take study drug home . A staff member explain participant fill diary . The study staff review diary participant every study visit give new diary beginning every cycle start . Study Visits : Every week first 6 week every 4-8 week participant leaf study , follow test procedure perform : - Participant physical exam , include measurement weight , vital sign . - Participant bone marrow aspiration biopsy do treatment start somewhere day 14 day 17 first Sorafenib administration . Another bone marrow sample collect day 24 28 . - If participant continue study , another bone marrow sample collect third cycle . - Blood ( 1 teaspoon ) drawn every 2-4 day routine test participant take study drug week day take study drug Plerixafor Neupogen . - During first week , blood ( 1 teaspoon ) drawn check status disease dose filgrastim plerixafor combination 4 8 hour receive study drug . If participant 's doctor feel need , additional blood may draw 2nd blood draw check status disease . If participant 's doctor feel need , blood draw may continue first week disease respond . Length Study : Participant may continue take study drug 6 cycle ( 6 month ) . If participant complete remission , partial remission , complete remission incomplete platelet count recovery 6 month intolerable side effect , doctor may discuss continue study . Participant take study disease get bad intolerable side effect occur . Follow-up Visits : If participant complete remission , doctor think best interest , may follow-up visit every 3 month study close . - Blood ( 2 teaspoon ) draw routine test . - Participant bone marrow biopsy and/or aspirate check status disease . End-of-Study Visit : Participant end-of-study visit 30 day last dose study drug . At visit , follow test procedure perform : - Participant physical exam , include measurement weight vital sign . - Blood ( 2 tablespoon ) draw routine test . - Participant bone marrow aspirate biopsy check status disease . This investigational study . Sorafenib FDA-approved commercially available treatment advance renal cell cancer ( RCC ) hepatocellular cancer ( HCC ) remove surgery . Its use patient AML investigational . Plerixafor FDA-approved commercially available use boost number hematopoietic stem cell ( HSC ) stem cell collection transplant ( combination filgrastim ) participants non-Hodgkin 's lymphoma ( NHL ) multiple myeloma ( MM ) . Its use participant AML investigational . Filgrastim ( NeupogenÒ ) FDA-approved commercially available use boost white blood cell production participant low blood cell count cause chemotherapy ( nonmyeloid malignancy , acute myeloid leukemia , bone marrow transplantation ) , treat severe chronic neutropenia ( SCN-low blood count ) , boost production hematopoietic progenitor cell patient undergo peripheral blood progenitor cell ( PBPC ) collection . Up 28 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients 18 year age old . 2 . Patients must relapsed/refractory leukemia FLT3 ( ITD ) mutation . Patients AML FLT3 mutation eligible frontline standard therapy , refuse treat intensive chemotherapy , may eligible . 3 . Serum biochemical value follow limit unless consider due leukemia : creatinine &lt; /= 1.5 mg/dl ; total bilirubin &lt; /= 1.5 mg/dL , unless increase due hemolysis congenital disorder ; transaminase ( SGPT ) &lt; /= 2.5 x upper limit normal ( ULN ) 4 . Able take oral medication . 5 . Able understand provide sign informed consent . 6 . Ejection fraction screen must &gt; /=50 % . 7 . Performance status &lt; 3 , unless directly relate leukemic disease process determine Principal Investigator . 1 . Subjects acute promyelocytic leukemia . 2 . Patients absolute blast count &gt; 20 k/uL . 3 . Nursing woman , woman childbearing potential positive urine pregnancy test , woman childbearing potential willing maintain adequate contraception ( birth control pill , intrauterine device ( IUD ) , diaphragm , abstinence , condom partner ) entire course study . 4 . Men willing maintain adequate contraception partner entire course study . 5 . Hypertension &gt; 140 mmHg systolic OR &gt; 90 mmHg diastolic without antihypertensive therapy . 6 . Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . 7 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Sorafenib contraindicate patient know severe hypersensitivity sorafenib excipients . 8 . Known human immunodeficiency virus ( HIV ) infection active Hepatitis B C. 9 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 10 . Pulmonary hemorrhage/bleeding event &gt; /= CTCAE Grade 2 within 4 week first dose study drug . 11 . Any hemorrhage/bleeding event &gt; /= CTCAE Grade 3 within 4 week first dose study drug . 12 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . 13 . Currently use St. John 's Wort rifampin . 14 . Known suspected allergy sorafenib agent give course trial . 15 . Active clinically serious uncontrolled infection &gt; CTCAE Grade 2 . 16 . Serious nonhealing wound , ulcer , bone fracture . 17 . Patients currently receive standard investigational treatment hematologic malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>myeloid leukemia</keyword>
	<keyword>mutate fms-like tyrosine kinase receptor-3</keyword>
	<keyword>FLT3 Mutations</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Granulocyte Colony Stimulating Factor</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Mobozil</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>BAY 43-9006</keyword>
</DOC>